ADC Therapeutics

ZYNLONTA

Manufacturer:

ADC Therapeutics

Zynlonta HCPCS:

J9359

HCPCS Code Descriptor:

Injection, loncastuximab tesirine-lpyl, 0.075 mg

Category:

J Code

Zynlonta NDCs:

79952-0110-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Zynlonta:

ZYNLONTA is an Oncology drug manufactured by ADC Therapeutics and administered via the Intravenous route of administration. The J Code: J9359 is aligned to the drug ZYNLONTA.

ACCESS PRICING AND MORE BY REGISTERING

J9359 Added Date:

April 1, 2022

J9359 Effective Date:

April 1, 2022

J9359 Termination Date:

HCPCS Active

Zynlonta billing and coding information can be found through Adc Therapeutics at the link below:
Zynlonta patient assistance information can be found through ADVANCING Patient Support at the URL: https://www.advancingpatientsupport.com/hcp/#enroll-your-patient-now
ZYNLONTA prescribing information can be found at the link below:
Information regarding ZYNLONTA’s side effects can be found at MedlinePlus